Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 74k | -- | 1963 |
| Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | CEO & Director | 867.85k | -- | 1962 |
| Ms. Lisa A. Locklear M.B.A. | CFO & Treasurer | 472.27k | -- | 1962 |
| Mr. Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary | 554.05k | -- | 1968 |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs | -- | -- | 1971 |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer | -- | -- | 1970 |
| Ms. Elly Ryu | VP & Corporate Controller | -- | -- | 1982 |
| Mr. Michael Mannarino | VP & Corporate Controller | -- | -- | -- |
Longeveron Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 23
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 17, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
April 16, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission